US EditionPublished • loading... • Updated
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
Vertex gains exclusive global rights to develop and commercialize a preclinical trispecific T-cell engager for B-cell autoimmune diseases, with WuXi providing R&D and receiving milestone payments.
- On Feb. 2, 2026, WuXi Biologics licensed a preclinical trispecific T‑cell Engager to Vertex in Shanghai.
- Vertex said the agreement provides `another important tool` to accelerate efforts, with WuXi framing the collaboration as validation of its CRDMO model.
- WuXi Biologics employs over 12,000 skilled employees supporting 945 client projects as of recent years.
- Under the agreement, WuXi will provide contract research and development services on next‑generation TCEs and is eligible for upfront, milestone payments, plus royalties.
- Licensing a trispecific T‑cell Engager positions Vertex to explore treatments for patients with B‑cell mediated autoimmune diseases, signaling industry interest in next‑generation multispecific modalities.
Insights by Ground AI
61 Articles
61 Articles
InsideNoVA.com+60 Reposted by 60 other sources
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an…
Coverage Details
Total News Sources61
Leaning Left4Leaning Right10Center24Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
11%
C 63%
R 26%
Factuality
To view factuality data please Upgrade to Premium
